CJC-1295 is a growth hormone releasing hormone analog studied for its extended signaling at the GHRH receptor. This collection groups CJC1295 without DAC with the CJC No DAC and Ipamorelin blend and ipamorelin, bringing together the compounds most often combined in growth hormone axis research. Every item is supplied for research use only.
CJC-1295 is studied for a longer signaling window than native GHRH, which lets researchers observe sustained stimulation of the pathway.
It is frequently combined with ipamorelin, a ghrelin receptor agonist, so researchers can study two GH pathways at once.
Placed next to sermorelin and tesamorelin, CJC-1295 helps compare GHRH analogs by half life and duration.
The collection centers on CJC1295 without DAC. It is grouped with the CJC No DAC and Ipamorelin blend, a ready combination of the two pathways, and Ipamorelin as the standalone ghrelin receptor agonist. Together they cover the core of combined secretagogue research.
Reconstitute lyophilized CJC-1295 with bacteriostatic water, adding solvent slowly and swirling gently to protect the peptide.
Keep sealed vials cold and store reconstituted material refrigerated, limiting freeze thaw cycles.
Record concentrations, lot numbers, and dates so results remain reproducible.
CJC-1295 is a GHRH analog studied for its extended stimulation of growth hormone release.
It refers to a version without the drug affinity complex, which gives a shorter half life than the DAC modified form.
The two act on different receptors, so together they are used to study complementary GH pathways.
All items are supplied as research grade material with documentation available for laboratory verification.
No. Every product in this collection is for laboratory research only and not for human or veterinary use.
This collection keeps CJC-1295 and its paired compounds together for laboratory work on the growth hormone axis. All products in this collection are supplied for laboratory and research use only. They are not for human or veterinary use.
